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Abstract
Background: To determine whether optimal use of serial measurements of serum levels of soluble cell adhesion
molecules (CAM) can improve monitoring of disease activity in SLE.
Methods: Serum levels of soluble CAM and conventional SLE biomarkers were measured in serial samples (n = 80)
from 21 SLE patients during and after flare and correlated in longitudinal analysis with disease activity determined
by ECLAM score. Blood samples from a second cohort of 34 SLE patients were subject to flow cytometry to
correlate serum biomarkers with B cell subsets.
Results: By adjusting for the baseline level (at the first visit), delta soluble vascular cell adhesion molecule-1
(sVCAM-1) showed stronger correlation with changes in ECLAM score and improved sensitivity and specificity for
identifying SLE responders versus non-responders compared to conventional SLE biomarkers including anti-dsDNA
antibody titre and complement C3. Multiple regression analysis identified delta sVCAM-1 as the best marker of SLE
clinical response. sVCAM-1 levels were significantly correlated with CD95+CD27+ activated memory B cells, CD95+
plasmablasts and circulating plasma cell numbers in SLE patients.
Conclusion: Subtracting a baseline level of sVCAM-1 for each individual substantially improved its utility as a
biomarker. Delta sVCAM-1 was superior to conventional SLE biomarkers for monitoring changes in disease activity.
This suggests that serial monitoring of serum sVCAM-1 trends should be considered in SLE patients to document
responses to treatment. We hypothesise that the correlation between activated B cell subsets and circulating
plasma cell numbers with soluble VCAM-1 serum levels in SLE may relate to the important role of VCAM-1 in B
lymphocyte survival and maturation in bone marrow and secondary lymphoid tissues.
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Background
Cell adhesion molecules (CAM) enable leukocyte adhe-
sion and rolling along endothelial cell surfaces, and con-
trol migration of leukocytes into inflamed tissues [1].
With the aid of chemokines and chemoattractants,
CAM regulate leukocyte circulation and allow lymphoid
cells to home in on specific tissues or inflammatory sites.
Adhesion molecules can be classified into three main
groups: selectins, integrins and immunoglobulin su-
pergene family (IGSF) groups. Vascular cell adhesion
molecule-1 (VCAM-1) and intercellular adhesion
molecule-1 (ICAM-1) are IGSF group members which
are induced on endothelial cells in response to numer-
ous inflammatory cytokines, including tumour necrosis
factor (TNF) and interleukin (IL)-1, and bind integrin
partners on leukocytes. E-selectin and P-selectin are
also inducible on activated endothelium, with the latter
additionally expressed on platelets. Soluble versions of
VCAM-1, ICAM-1, E-selectin and P-selectin are shed
from endothelial cell surfaces and are readily detectable
in serum [2]. Soluble VCAM-1 (sVCAM-1) is the most
abundant of the circulating CAM, and shows the greatest
variation in serum level across a number of inflammatory
diseases, with the highest levels observed in active systemic
lupus erythematosus (SLE), renal allograft and septic shock
[3, 4]. sVCAM-1 levels are elevated in several auto-
immune rheumatic diseases including SLE and rheuma-
toid arthritis (RA) compared with healthy controls, but
results for other CAM are conflicting [5–9]. sVCAM-1
levels have been shown to correlate with SLE disease
activity in several studies [7–10], and generally appear
to correlate better with disease activity than sICAM-1
or soluble E-selectin (sE-selectin). Urinary sVCAM-1
has been proposed as a biomarker in lupus nephritis
[11–13]. High levels of sVCAM-1 have also been asso-
ciated with severity of thrombosis in patients with anti-
phospholipid syndrome [14].
As well as being induced on activated endothelial cells,
VCAM-1 is widely expressed on stromal cells in bone mar-
row and secondary lymphoid tissues, lymphatic endothe-
lium and follicular dendritic cells (FDC) [15, 16]. Germinal
centre dendritic cell (DC) expression of VCAM-1 is an im-
portant B-cell survival factor [17]. Bone marrow stromal
cell expression of VCAM-1 regulates several physiological
functions: retention/release of haemopoietic stem cell pro-
genitors [18, 19]; pre-pro B-cell maturation [20]; and ma-
ture B-cell homing to bone marrow leading to long-lived
plasma cell persistence [20–22]. VCAM-1 thus plays a
global role in lymphocyte trafficking and homeostasis of
lymphocyte development.
In the present study, we sought to refine the use of
sVCAM-1 as a biomarker in SLE, and to determine
whether longitudinal sampling of sVCAM-1 could be of
clinical utility in addition to conventional serum markers
of disease activity such as anti-double-stranded DNA
(anti-dsDNA) antibody levels and complement C3 and
C4 levels. We identified patients undergoing a flare of
SLE and serially assayed serum levels of soluble CAM to
determine whether soluble CAM either singly or in
combination with conventional serum markers of disease
activity could be used to more accurately monitor
decreasing disease activity following treatment. Elevated
sVCAM-1 levels during SLE flare have been previously
assumed to be due to endothelial activation. We hypo-
thesised that circulating VCAM-1 might also reflect ac-
celerated B-cell maturation in secondary lymphoid tissue
and/or abnormal turnover of lymphocyte progenitors
and long-lived plasma cells in bone marrow. In a second
cohort of SLE patients, we determined whether there
was any association between soluble CAM levels and
circulating B-cell subset numbers and B-cell activation.
Methods
Individuals
The study was approved by the UK National Research
Ethics Service prior to the commencement of the study.
All study participants provided written consent at the
time of first sample collection. All SLE individuals
fulfilled the American College of Rheumatology (ACR)
criteria for classification of SLE [23]. For longitudinal
analysis of serum biomarkers, 21 SLE patients (cohort 1)
were identified who were undergoing a flare of SLE,
defined as a significant increase in disease activity neces-
sitating a change in treatment and in all cases consistent
with the current consensus definition of lupus flare [24].
Repeated blood samples (n = 80) were obtained during
regular follow-up visits as part of standard care (average
time interval 4 months) with an aim of four samples per
patient. SLE disease activity at each clinic visit was
assessed by the European Consensus Lupus Activity
Measure (ECLAM) [25]. Blood samples were obtained
from a second, separate cohort of 34 SLE patients for
comparison of serum markers and B-cell subsets mea-
sured by flow cytometry (see later). Demographics and
active disease characteristics for both SLE cohorts are
summarised in Table 1.
Serum biomarker measurement
Serum levels of sVCAM-1, sICAM-1, sE-selectin and sol-
uble P-selectin (sP-selectin) were analysed by sandwich
enzyme-linked immunosorbent assay (ELISA) according to
the manufacturer’s instructions (R&D Systems, Abingdon,
UK). sVCAM-1 levels were measured in sera from four
healthy control individuals (mean ± standard error (SE) of
the mean 399.1 ± 105 ng/ml), comparable with previous
studies [14]. The erythrocyte sedimentation rate (ESR),
anti-dsDNA antibody levels, complement C3 and C4
levels, and C-reactive protein (CRP) were measured as part
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of routine clinical management of SLE patients. Anti-
dsDNA antibody levels were screened by Crithidia luciliae
immunofluorescence and assayed by radioimmunoassay
(Farr assay). Complement C3 and C4 levels were assayed
by nephelometry.
Flow cytometry
Fresh peripheral blood mononuclear cells were isolated
from blood obtained from 34 SLE individuals. Cells were
stained with LIVE/DEAD Fixable Blue Dead cell stain
(Invitrogen, Paisley, UK) to exclude dead cells, Fc recep-
tor blocked (Human TruStain FcX; BioLegend, Oxford,
UK) and surface stained using the following markers:
IgD-BrilliantViolet(BV)421 (IA6-2), CD19-BV510 (HIB19),
CD27-BV650 (O323), CD138-FITC or CD138-PE-Cy7
(MI15), CD24-PerCP-Cy5.5 (ML5), CD95-PE-Cy7 (DX2),
CD38-APC (HB7) and CD20-APC-H7 (2H7) from BioLe-
gend or BD. Cells were fixed with BD stabilising fixative re-
agent. Freshly stained cells were acquired on a 5 laser BD
SORP LSRFortessa instrument. BD CS&T beads were used
immediately prior to every sample run to maintain instru-
ment consistency throughout the entire study. Data were
analysed using FlowJo version 10 (Ashland, OR, USA).
Statistical analysis
Statistical analysis was performed using SPSS statistics
version 22 (IBM Corporation, Armonk, NY, USA) and R
statistics package version 3.1 (R Foundation for Statistical
Computing, Vienna, Austria). Biomarker performance was
analysed by receiver operating characteristic (ROC) curve
analysis, using the pROC package version 1.7.3 in R, and
Youden’s index was used to select the optimal discrimin-
atory threshold. A reduction in ECLAM score of 3 or
more (ΔECLAM ≤ –3) was used to define “clinically
meaningful” improvement in disease activity [26]. Delta
parameters were calculated by subtracting the value on
each individual’s first visit for each parameter. For analysis
of ΔECLAM, multiple linear regression was performed
with stepwise selection based on Akaike information cri-
teria (AIC), using a mixed-effects model to account for
within-individual correlation because of repeated mea-
sures for each individual over time. The CD138+ plasma
cell population size expressed as the percentage of B cells
was analysed by multiple linear regression with stepwise
selection and beta regression to account for the standard
unit interval of this variable. Standardisation was applied
to predictors in all models.
Results
A total of 80 samples were assayed from 21 patients with
a median of four samples per patient, covering a median
follow-up duration of 16.5 months (interquartile range
12.0–21.3 months). Demographics for this first cohort of
SLE patients are summarised in Table 1. Using Spearman
rank correlation, the anti-dsDNA titre by radioimmuno-
assay (Farr) (r = 0.608, P = 2.2 × 10−9) and ESR (r = 0.584)
showed the strongest correlations with ECLAM score,
while sVCAM-1 levels (r = 0.571, P = 4.0 × 10−8) were
more highly correlated than complement C3 (r = −0.510)
and C4 (r = −0.416) levels (Fig. 1a, Table 2). sICAM-1, sE-
selectin and sP-selectin were not significantly correlated
with SLE disease activity. However, when using a mixed-
effects model to account for repeated measures over time,
sVCAM-1 showed a better fit (P = 2.4 × 10−10) than other
parameters including conventional serum markers.
ROC curve analysis was performed for each biomarker
using a cutoff value for ECLAM score of greater than 3
Table 1 Patient demographics and clinical characteristics at
time of enrolment
Demographic variable Cohort 1 (n = 21) Cohort 2 (n = 34)
Female 19 (90 %) 31 (91 %)
Age, median (interquartile range) 41.0 (34.3–51.3) 44.5 (36.0–52.0)
Samples per patient,
median (range)
4 (2–7) 1 (1–1)
Follow-up duration (months),
median (interquartile range)
16.5 (12.0–21.3) −
Active SLE disease features
Cutaneous 10 (48 %) 19 (56 %)
Arthritis 4 (19 %) 13 (38 %)
Serositis 5 (24 %) 2 (6 %)
Renal 12 (57 %) 11 (32 %)
Neurologic 5 (24 %) 3 (9 %)
Haematologic 16 (76 %) 17 (50 %)
dsDNA-positive 15 (71 %) 19 (56 %)
Low C3/C4 13 (62 %) 15 (44 %)
Other SLE serology
ANA-positive 17 (81 %) 33 (97 %)
Ro/La-positive 4 (19 %) 18 (53 %)
Sm/RNP-positive 3 (14 %) 22 (65 %)
Active treatment
Initial prednisolone dose (mg/day),
median (range)
15 (0-35) 5 (0-25)
Maintenance prednisolone
dose (mg/day), median (range)
7.5 (0-30) −
Mycophenolate mofetil 11 (52 %) 9 (26 %)
Azathioprine 10 (48 %) 6 (18 %)
Hydroxychloroquine 10 (48 %) 19 (56 %)
Methotrexate 0 (0 %) 6 (18 %)
Tacrolimus/everolimus 0 (0 %) 2 (6 %)
Previous treatment
Intravenous cyclophosphamide 11 (52 %) 3 (9 %)
Intravenous immunoglobulin 2 (10 %) 0 (0 %)
dsDNA double-stranded DNA, SLE systemic lupus erythematosus, ANA anti-
nuclear antibody , Sm anti-Smith, RNP anti-ribonucleoprotein
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Fig. 1 (See legend on next page.)
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(ECLAM >3) as a “clinically meaningful” measure of
active versus inactive SLE [26]. sVCAM-1 was the only
soluble CAM to be able to distinguish active lupus
(area under curve (AUC) 0.796, 95 % CI 0.689 − 0.894),
but performed less well than anti-dsDNA titre by both
AUC and Youden index measures (Table 2). As expected,
the anti-dsDNA titre was the most specific test of the con-
ventional serum markers for identifying patients with high
disease activity, while complement C3 and ESR were the
most sensitive tests in this group of patients. This observa-
tion is consistent with previous reports which suggested
that sVCAM-1 was superior to other soluble CAM in
terms of correlation with disease activity [6, 7], but did
not improve upon conventional markers for identifying
active versus inactive disease [8].
Since sVCAM-1 showed the strongest fit with ECLAM
when a mixed-effects model was applied, we postulated
that this could be explained by variability in baseline
sVCAM-1 levels between individuals because of comor-
bidities such as atherosclerosis. To account for in-
dividual variation, changing levels of each biomarker
(delta measurements) were calculated by subtracting
baseline (first visit) values for each variable and correlat-
ing each biomarker with changing levels of ECLAM
score (ΔECLAM) (Fig. 1b). Surprisingly ΔsVCAM-1
demonstrated the strongest correlation with ΔECLAM
(Spearman correlation, r = 0.622, P = 9.7 × 10−10), com-
pared with Δanti-dsDNA titre (r = 0.292, P = 0.0085),
ΔC3 level (r = −0.367, P = 8.0 × 10−4) and ΔC4 level
(r = −0.274, P = 0.014) (Table 3). Using a mixed-effects
model incorporating time as a subject-specific effect,
ΔsVCAM-1 (P = 3.85 × 10−9) still showed the best fit with
ΔECLAM compared with all other parameters. Responders
were defined as a showing a “clinically meaningful” fall in
ECLAM score of 3 or more (ΔECLAM score ≤ –3) com-
pared with nonresponders (ΔECLAM> –3) [26]. Even a
simple comparison of biomarker levels in responders ver-
sus nonresponders (Fig. 1c) showed that ΔsVCAM-1 dem-
onstrated the widest delineation between responders and
nonresponders (unpaired t test, P <0.0001) compared with
dsDNA (P = 0.013) and C3 (P = 0.0011). ROC curve ana-
lysis confirmed that ΔsVCAM-1 (AUC 0.899, Youden
index 0.703) had the best performance characteristics for
identifying responders and nonresponders as determined
by both ROC AUC and Youden index as compared with
Δcomplement C3 (AUC 0.772, Youden index 0.639),
ΔdsDNA (AUC 0.731, Youden index 0.550) and all other
biomarkers measured (Fig. 1d, Table 3). Based on the
Youden index, ΔsVCAM-1 showed the highest sensitivity
(86.4 %) of all parameters compared with a sensitivity of
(See figure on previous page.)
Fig. 1 Subtraction of baseline improves biomarker ability of sVCAM-1 for tracking longitudinal changes in SLE disease activity. a sVCAM-1 assayed
by ELISA and compared with SLE disease activity measured by ECLAM score. Correlation with ECLAM score is shown for conventional markers of
disease activity: anti-dsDNA antibody titre by Farr radioimmunoassay, complement C3 level and ESR. Dotted lines represent laboratory lower limit
for C3 to show individuals with hypocomplementaemia. Statistical analysis by Spearman correlation. b Correlation plots showing change in biomarker
level against change in ECLAM score for sVCAM-1 compared with conventional serum biomarkers of SLE disease activity. Delta values for each
parameter were calculated by subtracting the parameter value at the first visit for each individual. c Comparison of biomarker levels in SLE responders
(ΔECLAM≤−3) versus nonresponders (ΔECLAM> −3) for ΔsVCAM-1, Δanti-dsDNA titre, ΔC3 level and ΔESR. Bars represent mean ± standard deviation.
Statistical analysis by unpaired t test. d ROC curves for changing levels of serum biomarkers for detection of clinical response in SLE (ΔECLAM≤−3).
e Graph showing interval time course of ΔsVCAM-1 levels compared with ΔECLAM score. dsDNA double-stranded DNA, ECLAM European Consensus
Lupus Activity Measure, ESR erythrocyte sedimentation rate, sE-selectin soluble E-selectin, sICAM-1 soluble intercellular adhesion molecule-1, sP-selectin
soluble P-selectin, sVCAM-1 soluble vascular cell adhesion molecule-1
Table 2 Performance characteristics of biomarkers to detect active SLE (ECLAM score >3)
Spearman correlation Mixed-effects ROC curve analysis
Biomarker r value P value P value AUC (95 % CI) Youden index Sensitivity (%) Specificity (%) PPV (%) NPV (%)
sVCAM-1 0.571 4.0 × 10−8 2.4 × 10−10 0.796 (0.689 − 0.894) 0.546 82.1 72.5 74.4 80.6
sICAM-1 −0.067 NS NS 0.536 (0.407 − 0.663) 0.175 20.0 97.5 88.9 54.9
sE-selectin 0.066 NS 1.3 × 10−2 0.496 (0.363 − 0.628) 0.200 47.5 72.5 63.3 58.0
sP-selectin −0.111 NS NS 0.535 (0.401 − 0.667) 0.200 67.5 52.5 58.7 61.8
ESR 0.584 1.6 × 10−8 7.1 × 10−7 0.818 (0.717 − 0.908) 0.543 82.5 71.8 75.0 80.0
dsDNA 0.608 2.2 × 10−9 1.1 × 10−5 0.832 (0.732 − 0.920) 0.600 75.0 85.0 83.3 77.3
C3 −0.510 1.0 × 10−6 1.8 × 10−7 0.804 (0.698 − 0.892) 0.500 82.5 67.5 71.7 79.4
C4 −0.416 1.3 × 10−4 2.2 × 10−3 0.744 (0.631 − 0.846) 0.450 77.5 67.5 70.5 75.0
AUC area under ROC curve, CI confidence interval, dsDNA double-stranded DNA, ECLAM European Consensus Lupus Activity Measure, ESR erythrocyte sedimentation
rate, NPV negative predictive value, NS not significant, PPV positive predictive value, r Spearman correlation for each parameter against ECLAM, ROC receiver operating
characteristic, sE-selectin soluble E-selectin, sICAM-1 soluble intercellular adhesion molecule-1, SLE systemic lupus erythematosus, sP-selectin soluble P-selectin,
sVCAM-1 soluble vascular cell adhesion molecule-1
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81.8 % for both ΔC3 and ΔdsDNA. The optimal cutoff
value for ΔsVCAM-1 corresponded to a reduction in
sVCAM-1 level of 182 ng/ml. ΔsVCAM-1 also had a higher
specificity (83.9 %) compared with both ΔC3 (82.1 %) and
ΔdsDNA (73.2 %). Although ΔESR (89.3 %) and ΔsE-
selectin (92.9 %) had higher specificity than ΔsVCAM-1,
both had very poor sensitivity (40.9 %). ΔsVCAM-1
showed the highest negative predictive value (94.0 %) of
all parameters, and demonstrated a higher positive pre-
dictive value (67.9 %) compared with conventional bio-
markers ΔC3, ΔC4, ΔdsDNA and ΔESR for estimating
improvement in the ECLAM score (Table 3). Further-
more, if specificity was more stringently fixed at 90 %, the
sensitivity of ΔsVCAM-1 (77.3 %) was substantially super-
ior to conventional biomarkers (ΔESR 40.9 %, ΔdsDNA
27.3 %, ΔC3 31.8 %) and other CAM. Plotting ΔsVCAM-1
and ΔECLAM across 4-monthly time intervals showed
that ΔsVCAM-1 effectively tracks ΔECLAM over time
(Fig. 1e), consistent with the results of the mixed-effects
model. In an analysis of renal SLE patients, ΔsVCAM-1
showed a marginally stronger correlation with proteinuria
(r = 0.27, P = 0.0041) compared with unadjusted sVCAM-
1 (r = 0.22, P = 0.011) (Additional file 1: Figure S1A, B).
ΔsVCAM-1 also showed significant correlation with
ΔECLAM in SLE individuals with negative dsDNA titres
(r = 0.57, P <0.0001) (Additional file 1: Figure S1C)
and in normocomplementaemic SLE individuals (r = 0.46,
P = 0.0002) (Additional file 1: Figure S1D). This suggests
that ΔsVCAM-1 has utility in a subset of SLE patients
where standard SLE biomarkers such as dsDNA antibody
titre and complement C3/C4 levels fail to reflect disease
activity. However, we acknowledge that the present study
is limited by numbers for these subgroup analyses, and a
larger longitudinal study of ΔsVCAM-1 is required to con-
firm the usefulness of ΔsVCAM-1 in these SLE subgroups.
Overall these results suggest that the ΔsVCAM-1 level was
the best biomarker for forecasting changes in ECLAM
score and identifying responders versus nonresponders.
Further analysis was performed by multiple linear re-
gression with stepwise selection using the following
standardised variables: age, ΔC3, ΔC4, ΔdsDNA titre,
ΔESR, ΔsVCAM-1, ΔsICAM-1, ΔsE-selectin and ΔsP-
selectin. A mixed-effects model was applied to take ac-
count of longitudinal measurements for each subject
over time. As summarised in Table 4, both models iden-
tified two parameters, ΔsVCAM-1 (P = 8.6 × 10−7) and
ΔC3 (P = 8.8 × 10−4), as being the optimal model for esti-
mating improvement in disease activity measured by
ΔECLAM score (P = 6.0 × 10−4 for combined model
compared with ΔsVCAM-1 alone). The final model
yielded the following equation for estimating ΔECLAM
using ΔsVCAM-1 (expressed in ng/ml) and ΔC3
(expressed in g/l):
Estimated ΔECLAM ¼ ΔsVCAM‐1½ 
 0:00235 – ΔC3½ 
 4:78 – 0:537
We tested this ΔsVCAM-1 and ΔC3 composite bio-
marker in our cohort to see whether it was an improve-
ment compared with the use of ΔsVCAM-1 alone, and it
made a marginal improvement to the AUC (0.927 95 %
Table 3 Performance characteristics of biomarkers to detect clinical response in SLE (reduction in ECLAM score of 3 or more)
Spearman correlation Mixed-effects ROC curve analysis
Biomarker r value P value P value AUC (95 % CI) Youden index Sensitivity (%) Specificity (%) PPV (%) NPV (%)
ΔsVCAM-1 0.622 9.7 × 10−10 3.9 × 10−9 0.899 (0.808 − 0.968) 0.703 86.4 83.9 67.9 94.0
ΔsICAM-1 0.357 0.0012 3.4 × 10−5 0.688 (0.537 − 0.824) 0.426 72.7 69.9 48.5 86.7
ΔsE-selectin 0.162 NS 1.0 × 10−4 0.569 (0.382 − 0.737) 0.338 40.9 92.9 69.2 80.0
ΔsP-selectin −0.092 NS NS 0.541 (0.385 − 0.692) 0.287 59.1 69.6 43.3 81.2
ΔESR 0.211 0.062 8.3 × 10−5 0.586 (0.417 − 0.738) 0.302 40.9 89.3 60.0 79.4
ΔdsDNA 0.292 0.0085 0.052 0.731 (0.581 − 0.860) 0.550 81.8 73.2 54.5 91.1
ΔC3 −0.367 8.0 × 10−4 2.9 × 10−4 0.772 (0.634 − 0.890) 0.639 81.8 82.1 64.3 92.0
ΔC4 −0.274 0.014 NS 0.689 (0.543− 0.821) 0.406 72.7 67.9 47.1 86.4
AUC area under ROC curve, CI confidence interval, dsDNA double-stranded DNA, ECLAM European Consensus Lupus Activity Measure, ESR erythrocyte sedimentation
rate, NPV negative predictive value, NS not significant, PPV positive predictive value, r Spearman correlation for each parameter against ΔECLAM, ROC receiver operating
characteristic, sE-selectin soluble E-selectin, sICAM-1 soluble intercellular adhesion molecule-1, SLE systemic lupus erythematosus, sP-selectin soluble P-selectin,
sVCAM-1 soluble vascular cell adhesion molecule-1
Table 4 Multiple linear regression and mixed-effects model
analyses for ΔECLAM as a dependent variable
Multiple linear regression Mixed-effects model
Estimate (SE) P value Estimate (SE) P value
ΔsVCAM-1 1.126 (0.202) 3.5 × 10−7 1.280 (0.231) 8.6 × 10−7
ΔC3 −0.764 (0.202) 3.0 × 10−4 −0.708 (0.201) 8.8 × 10−4
ECLAM European Consensus Lupus Activity Measure, SE standard error,
sVCAM-1 soluble vascular cell adhesion molecule-1
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CI 0.872–0.983). However, at specificity levels above
80 % it did not significantly improve upon the sensitivity
or specificity of ΔsVCAM-1 alone. Although in practice
the ΔsVCAM-1 and ΔC3 composite biomarker did not
offer much improvement over the use of ΔsVCAM-1
alone, these results confirm that even with inclusion of
other parameters ΔsVCAM-1 is still the strongest estima-
tor of disease activity response as measured by change in
ECLAM score.
We postulated that the strong ability of ΔsVCAM-1 as
a biomarker of clinical response in SLE, compared with
sICAM-1 or sE-selectin which are also shed from acti-
vated endothelial cells, or CRP which is a known marker
of vascular inflammation [27], suggested that circulating
VCAM-1 levels could reflect factors other than endothe-
lial inflammation, such as aberrant lymphocyte homeo-
stasis in active SLE. B-cell subset numbers measured by
10-colour flow cytometry on fresh blood samples from a
second cohort of 34 SLE patients were compared with
the serum level of sVCAM-1 and conventional SLE serum
markers (gating strategy shown in Fig. 2a). The numbers of
total B cells, transitional B cells and naïve B cells were not
significantly correlated with levels of sVCAM-1 (data not
shown). However, the CD19midCD20−CD27hiCD38hiIgD−
CD138hi circulating plasma cell number showed correlation
with sVCAM-1 (Pearson’s correlation, r = 0.50, P = 0.0092)
and ECLAM score (r = 0.40, P = 0.019), weak correlation
with the ESR (r = 0.35, P = 0.041) (Fig. 2b) and a non-
significant trend with dsDNA titre (r = 0.33, P = 0.088).
This result is consistent with previous reports showing
correlation between plasma cell number and SLE disease
activity [28]. We observed significant correlation between
serum sVCAM-1 levels and activated B-cell subsets includ-
ing CD95+CD27+ memory B cells (r = 0.62, P = 0.0099) and
CD95+ plasmablasts (CD19midCD20−CD27hiCD38hiIgD−)
(r = 0.66, P = 0.0055) (Fig. 2b, c), consistent with the in-
volvement of these subsets of activated mature B cells in
plasma cell generation. We also observed higher CD95
expression in plasmablasts (unpaired t test, P = 0.046)
and plasma cells (P = 0.042) of SLE patients with high
sVCAM-1 levels compared with low sVCAM-1 SLE
patients (Fig. 2d). sVCAM-1 levels also correlated with
CD95+ plasma cells (r = 0.61, P = 0.012), primarily because
the vast majority of plasma cells were CD95+. Although
the CD95+CD27− memory B-cell subset has been shown
to be increased in SLE in association with disease flares
[29], we did not observe any correlation between the
CD95+CD27− subset of memory B cells and sVCAM-1 in
this small cohort.
Multiple linear regression with beta regression was
performed using the following standardised variables:
sVCAM-1, ECLAM score, dsDNA, C3, C4, ESR and
CRP. Beta regression was applied because plasma cell
numbers (expressed as a percentage of live B cells)
assume values within the standard unit interval. Stepwise
selection identified a three-variable model including ESR,
sVCAM-1 and ECLAM score. Both ESR (estimate (SE) –
0.475 (0.226), P(>|z|) = 0.035) and sVCAM-1 (estimate
(SE) 0.314 (0.153), P = 0.040) reached statistical sig-
nificance by beta regression, while ECLAM showed bor-
derline statistical significance (estimate (SE) 0.346 (0.190),
P = 0.068). These results show that the correlation be-
tween sVCAM-1 levels and plasma cell numbers remains
statistically significant even after adjustment for the
known association between sVCAM-1 and ECLAM score.
Discussion
These results recapitulate previous studies which have
shown that serum levels of sVCAM-1 track disease ac-
tivity in SLE [6, 7]. However consistent with these previ-
ous studies, we found that absolute levels of sVCAM-1
were less useful as a diagnostic tool for identifying SLE
patients with active disease than other conventional
markers such as dsDNA antibody titre and C3 levels [8],
presumably due to intrinsic variability in sVCAM-1 le-
vels between individuals. The key novel finding in our
study is that subtracting a baseline level of sVCAM-1
significantly improved its biomarker abilities. We ob-
served that the trend in changing levels of sVCAM-1 is
a stronger marker of clinical response as measured by
reduction in ECLAM score, compared with conventional
serum markers of SLE disease activity (anti-dsDNA anti-
body, complement C3 and C4 levels, ESR), as well as
other soluble CAM (sICAM-1, sE-selectin, sP-selectin).
Our data show that a reduction in sVCAM-1 level of
182 ng/ml showed the highest sensitivity (86.4 %) for
identifying responders, defined as showing a “clinically
meaningful” fall in ECLAM score of −3, with compar-
ably high specificity (83.9 %). Multiple linear regression
analysis showed that ΔsVCAM-1 and ΔC3 are the two
best markers of clinical response (as measured by
ΔECLAM), and confirmed that ΔsVCAM-1 is the best
single marker of clinical response in SLE. We tested a
composite score of both ΔsVCAM-1 and ΔC3 and found
that it showed better correlation with ΔECLAM, but did
not usefully improve sensitivity and specificity compared
with using ΔsVCAM-1 alone. We cannot rule out that
in certain circumstances monitoring trends in serum
levels of both sVCAM-1 and C3 may be a better method
of tracking flares and response to therapy in SLE, al-
though this will need to be determined in a larger study,
to see whether particular subsets of patients benefit from
a composite score including both parameters.
In the past, increased serum levels of sVCAM-1 have
been attributed solely to endothelial activation and a
large number of studies have examined serum levels of
CAM in vascular disease and other conditions. In
general, these studies show that sICAM-1 is a better
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predictor of future cardiovascular events, and mostly
show that serum concentrations of sVCAM-1 and
sICAM-1 are only modestly increased in coronary artery
disease and diseases associated with endothelial dysfunc-
tion. This is consistent with evidence that sICAM-1
levels more closely reflect levels of systemic endothelial
dysfunction than sVCAM-1 [30]. In contrast, levels of
sVCAM-1 observed in patients with high SLE disease ac-
tivity are among the highest levels of sVCAM-1 observed,
showing levels comparable with patients with septic shock
[4]. Our observation that sVCAM-1 levels track SLE dis-
ease activity far more strongly than sICAM-1, sE-selectin
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or sP-selectin suggests that fluctuations in sVCAM-1
levels reflect other physiological processes distinct from
endothelial activation.
Surprisingly little is known of the physiological condi-
tions required for the release of soluble CAM. VCAM-1,
ICAM-1 and E-selectin are not constitutively expressed on
the surface of endothelial cells, but are upregulated in re-
sponse to stimulation such as by TNF, and during this
process sVCAM-1, sICAM-1 and sE-selectin are shed
from the cell membrane [2]. CAM expression is necessary
for leukocyte adherence and migration into inflamed
tissues, but shedding of VCAM-1 is not necessary for
leukocyte detachment from endothelial surfaces during
transendothelial migration, since this process is facilitated
by calpain-mediated integrin cleavage [31]. This fits with
lupus mouse model studies which show that although local
VCAM-1 expression is elevated in lupus-affected organs
[32], ICAM-1 is more critical for transendothelial migra-
tion of leukocytes into inflamed tissues [33, 34]. Cleavage
of VCAM-1 from activated endothelial cells is predomin-
antly mediated by TNFα converting enzyme (TACE,
ADAM17) and regulated by TIMP-3 [35, 36], although
other ADAM family metalloproteinases may also be in-
volved [37]. Another situation in which VCAM-1 is delib-
erately shed is during granulocyte-colony stimulated factor
(G-CSF)-induced mobilisation of haemopoietic stem cell
progenitors from bone marrow [18, 19]. Notably the rise
in serum sVCAM-1 induced by G-CSF is of a similar mag-
nitude to that of active SLE patients.
VCAM-1 plays an important role at several key points of
lymphocyte development because of its widespread ex-
pression on stromal cells in secondary lymphoid tissues
[15, 16]. VCAM-1 is highly expressed on activated FDC
[38, 39] where it serves two key purposes: VCAM-1 rescues
B cells from apoptosis [17], and VCAM-1 is a prerequisite
for DC to B cell immunological synapse during B-cell
receptor antigen presentation [40]. VCAM-1 is highly
expressed on CXCL12+ (SDF-1) bone marrow stromal cells
and is required for both early pre-pro B-cell development
as well as long-lived plasma cell retention in bone marrow
[20]. Conditional deficiency of VCAM-1 in mice blocks B-
cell maturation, resulting in increased circulating immature
B cells, showing that VCAM-1 plays an important role in
homing of mature B cells to bone marrow [21, 22]. It is
unknown whether sVCAM-1 is shed during any of the
numerous cell–cell interactions between lymphocytes and
DC or other stromal cells which involve VCAM-1.
In the second part of our study, flow cytometric meas-
urement of B-cell subsets in a second cohort of SLE pa-
tients revealed that sVCAM-1 levels were correlated with
circulating plasma cell numbers, confirmed by multiple
regression analysis. High sVCAM-1 levels were associated
with increased expression of the activation marker CD95
in SLE plasmablasts and plasma cells. sVCAM-1 levels
were correlated with activated B-cell subsets including
CD95+CD27+ memory B cells and CD95+ plasmablasts,
consistent with the importance of these B-cell subsets in
aberrant plasma cell development in SLE [29]. sVCAM-1
could be derived from multiple sources: activated endo-
thelium, bone marrow stromal cells, lymphatic endothe-
lium and activated DCs. However, the relative quantities
of sVCAM-1 shed from each of these sources are un-
known. It is plausible that elevated serum levels of
VCAM-1 in SLE patients not only reflect widespread
endothelial activation in response to SLE-mediated tissue
damage, but may reflect other active immune processes
such as haematopoietic cell turnover in bone marrow,
leukocyte trafficking via the lymphatic system, B-cell mat-
uration by germinal centre FDC and homing/maintenance
of long-lived plasma cells to bone marrow. This fits with
our data indicating that sVCAM-1 showed a much stron-
ger correlation with fluctuating SLE disease activity com-
pared with sICAM-1 and sE-selectin, whose levels reflect
systemic endothelial activation. sVCAM-1 may be released
during times of increased lymphocyte turnover as a direct
reflection of immunological changes during active SLE,
which might explain the association between increased
activated CD95+CD27+ memory B cells, CD95+ plasma-
blasts and circulating plasma cell numbers in SLE with
higher serum levels of sVCAM-1.
Conclusions
Our study has shown that serial monitoring of the trend
in sVCAM-1 levels compared with a baseline reference
level for each individual may be a useful additional bio-
marker for monitoring disease activity in SLE, and in this
study population was superior to complement C3, dsDNA
titre and ESR for identifying clinical response. This
warrants further validation in larger SLE cohorts. The lim-
itations of current markers of SLE disease activity are well
recognised [41]: a significant proportion of SLE patients
are either persistently negative for anti-dsDNA antibodies
or do not develop hypocomplementaemia. Hence there is
a major need for additional biomarkers which can im-
prove monitoring of SLE disease activity and response to
therapy. Our data suggest that serial measurements of
ΔsVCAM-1 could lead to improved monitoring of clinical
response to therapy in SLE and may be a useful novel
outcome measure in future clinical trials of SLE.
Additional file
Additional file 1: Figure S1. Showing analysis of ΔsVCAM-1 levels in
SLE subgroups. Plots showing correlation of A unadjusted sVCAM-1 and
B ΔsVCAM-1 levels with proteinuria levels in individuals with lupus nephritis.
Correlation of ΔsVCAM-1 with change in SLE disease activity measured
by ΔECLAM in C SLE individuals with negative dsDNA titres and
D normocomplementaemic SLE individuals. (PDF 36 kb)
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